Takeda's dengue vaccine QDENGA gets EU's authorisation use approval

Japanese company Takeda's dengue vaccine was authorised for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.
 

The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue.
 

There are no antivirals or specific treatments for the flu-like viral disease. While the illness is mostly mild, some people can develop life-threatening complications. Between 20,000 to 25,000 people, mostly children, die each year, according to the World Health Organization.
 

QDENGA follows Sanofi's Dengvaxia, which was